Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Baird Maintains Outperform on Homology Medicines, Lowers Price Target to $9

Baird Maintains Outperform on Homology Medicines, Lowers Price Target to $9

Baird analyst Madhu Kumar maintains Homology Medicines (NASDAQ:FIXX) with a Outperform and lowers the price target from $10 to $9.

August 31, 2022

1 minute read

Baird analyst Madhu Kumar maintains Homology Medicines (NASDAQ:FIXX) with a Outperform and lowers the price target from $10 to $9.

Tesla’s Cost-Cutting Battery Tech Engineer Jumps Ship To Massachusetts Startup: Another Blow For Musk?

October 20, 6:44 AM

During his four-year tenure at Tesla, Duong played a significant role as the lead inventor of the dry battery electrode (DBE) process.

October 2, 4:00 PM

Analysts have provided the following ratings for Okta (NASDAQ:OKTA) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

August 10, 4:29 AM

SVB Leerink analyst Whit Mayo maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and raises the price target from $24 to $29.

May 11, 9:21 AM

Alibaba Group Holding Limited (NYSE:BABA) co-founder and Executive Vice Chairman Joe Tsai sees AI tools as pivotal in transforming the future…